Study of LY4006895 to Assess Safety and Effects in Healthy Adults and Patients With Early Alzheimers Disease

What this Trial Is About

Researchers are evaluating the safety and tolerability of LY4006895, a study drug, in both healthy volunteers and participants with early symptomatic Alzheimers Disease AD. The study includes two parts Part A involves single-ascending doses in healthy participants, and Part B involves multiple-ascending doses in participants with early AD. The study aims to better understand how LY4006895 behaves in the body, including how much enters the bloodstream and how long it takes to be eliminated. Participants in Part A will receive single intravenous IV doses of LY4006895 or a placebo, while those in Part B will receive multiple IV doses of LY4006895 or placebo. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the drug or placebo. The entire study lasts approximately 29 weeks for Part A and 61 weeks for Part B, including screening periods. During the study, participants will have blood tests to measure drug levels and monitor safety. Researchers will track any treatment-related side effects, serious adverse events, and study discontinuations. Participants with early AD must have study partners who will assist with visits and provide consent. The primary outcome is the number of participants experiencing adverse events up to 61 weeks. The study includes regular assessments to ensure participant safety and gather pharmacokinetic data throughout the trial.

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)